[1] Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to
cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-
558. DOI: 10.1016/S2468-1253(19)30119-0.
[2]https://www2.deloitte.com/uk/en/pages/life-sciences-and healthcare/
articles/measuring-return-from-pharmaceutical-innovation.html
[3] Zeng N, Zou CL, He ZY, et al. Systematic review on reporting
quality of randomized controlled trials in patients with hepatitis B
or C in China[J]. Int J Infect Dis, 2018, 67: 58-64. DOI: 10.1016/
j.ijid.2017.11.011.
[4] US Food and Drug Administration. Adaptive design clinical trials
for drugs and biologics guidance for industry[EB/OL]. 12/02/2019.
Docket Number FDA-2018-D-3124. https://www.fda.gov/
media/78495/download.
[5] US Food and Drug Administration. Master protocols: efficient clinical
trial design strategies to expedite development of oncology drugs and
biologics [EB/OL]. 10/01/2018. Docket Number: FDA-2018-D-3292.
https://www.fda.gov/media/120721/download.
[6] Woodcock J, LaVange LM. Master protocols to study multiple
therapies, multiple diseases, or both[J]. N Engl J Med, 2017, 377(1):
62-70. DOI: 10.1056/NEJMra1510062.
[7] EMA Scientific Guidelines: Reflection paper on methodological issues
in confirmatory clinical trials planned with an adaptive design[EB/
OL]. https://www.ema.europa.eu/en/human-regulatory/research-
development/scientific-guidelines;2007.
[8] 國家藥品監督管理局藥品審評中心 . 藥物臨床試驗適應性設
計指導原則 ( 徵求意見稿 )[EB/OL]. http://www.cde.org.cn/news.
do?method= largeInfo&id=315068.
[9] Chow SC, Chang M. Adaptive design methods in clinical trials[M].
2nd edition. New York: Chapman and Hall/CRC Press.
[10] Chow SC, Lin M. Analysis of two-stage adaptive seamless trial
design[J]. Pharm Anal Acta, 2015, 6: 341. DOI: 10.4172/2153-
2435.1000341.
[11] Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and
endpoints of clinical trials in chronic hepatitis B - report from the 2019
EASL-AASLD HBV treatment endpoints conference[J]. Hepatology,
2019, in press. DOI: 10.1002/hep.31030.
[12] D'Amico G, Abraldes JG, Rebora P, et al. Ordinal outcomes are
superior to binary outcomes for designing and evaluating clinical
trials in compensated cirrhosis[J]. Hepatology, 2019 , in press. DOI:
10.1002/hep.31070.
[13]http://www.fda.gov/ora/compliance_ref/part11/FRs/background/
pt11finr.pdf
[14] US Food and Drug Administration. Guidance for industry, oversight
of clinical investigations-A risk-based approach to monitoring[EB/
OL]. 08/07/2013.Docket Number: FDA-2011-D-0597. https://www.
fda.gov/media/116754/download.
[15] US Food and Drug Administration. A risk-based approach to
monitoring of clinical investigations questions and answers[EB/OL].
03/15/2019. Docket Number: FDA-2019-D-0362. https://www.fda.
gov/media/121479/download.
[16] 國家藥監局 , 國家衛生健康委 . 《藥物臨床試驗質量管理規範》
2020 年 第 57 號 公 告 . http://www.nmpa.gov.cn/WS04/CL2138/
376852.html.
[17] Lin A, Chow SC. Data monitoring committees in adaptive clinical
trials[J]. Clinical Investigation, 2013, 3(7): 605-607. DOI: 10.4155/
cli.13.47.